Aptevo Therapeutics Inc. (APVO) intrinsic value & 10-year financials
Aptevo Therapeutics Inc. (APVO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.62
- Market cap
- $511.2K
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -33.6%
- ROIC (10-yr avg)
- -3140.2%
- Free cash flow (FY2025)
- —
APVO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$26.0M | -$87.27 | — | — | -26986.7% |
| FY2024 | — | -$24.1M | -$87.38 | — | — | -3487.0% |
| FY2023 | — | -$17.4M | -$1.42 | — | — | -623.2% |
| FY2022 | $3.1M | $8.0M | $1.57 | -$21.1M | -919.7% | -72.2% |
| FY2021 | $12.3M | -$28.5M | -$6.07 | -$22.4M | -174.1% | 381.5% |
| FY2020 | $4.3M | -$17.8M | — | -$29.4M | -638.1% | -102.1% |
| FY2019 | $32.4M | -$40.4M | — | -$42.5M | -131.4% | -194.3% |
| FY2018 | $23.1M | -$53.7M | — | -$52.4M | -224.0% | -95.0% |
| FY2017 | $14.7M | $7.0M | — | -$43.0M | -368.1% | -35.2% |
| FY2016 | $36.4M | -$112.4M | — | -$39.4M | -348.4% | -188.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aptevo Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aptevo Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -61.5% ROIC.
Aptevo Therapeutics Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Aptevo Therapeutics Inc. is modeled at -33.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-79.59 per share.